Zacks Research Issues Positive Outlook for FOLD Earnings

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Stock analysts at Zacks Research upped their Q1 2026 earnings per share (EPS) estimates for Amicus Therapeutics in a report released on Tuesday, April 1st. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $0.06 per share for the quarter, up from their prior forecast of $0.04. The consensus estimate for Amicus Therapeutics’ current full-year earnings is $0.15 per share. Zacks Research also issued estimates for Amicus Therapeutics’ Q2 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.13 EPS, FY2026 earnings at $0.36 EPS, Q1 2027 earnings at $0.10 EPS and FY2027 earnings at $0.56 EPS.

Several other research firms have also recently issued reports on FOLD. Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Wells Fargo & Company lowered their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, February 20th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Stock Up 0.5 %

FOLD opened at $7.99 on Wednesday. The firm has a market cap of $2.45 billion, a P/E ratio of -44.39, a PEG ratio of 1.51 and a beta of 0.69. The business’s fifty day simple moving average is $9.19 and its 200 day simple moving average is $9.90. Amicus Therapeutics has a 52 week low of $7.85 and a 52 week high of $12.65. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01.

Institutional Investors Weigh In On Amicus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in FOLD. Virtus Fund Advisers LLC acquired a new position in shares of Amicus Therapeutics in the 4th quarter valued at about $29,000. Covestor Ltd lifted its position in Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 2,312 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Amicus Therapeutics during the third quarter valued at approximately $55,000. GF Fund Management CO. LTD. purchased a new stake in Amicus Therapeutics during the fourth quarter worth approximately $59,000. Finally, R Squared Ltd acquired a new stake in shares of Amicus Therapeutics in the fourth quarter worth $79,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.